Replication data for: Cystatin C proteoforms in chronic kidney disease (doi:10.18710/NUNHDF)

View:

Part 1: Document Description
Part 2: Study Description
Part 5: Other Study-Related Materials
Entire Codebook

Document Description

Citation

Title:

Replication data for: Cystatin C proteoforms in chronic kidney disease

Identification Number:

doi:10.18710/NUNHDF

Distributor:

DataverseNO

Date of Distribution:

2021-04-30

Version:

1

Bibliographic Citation:

Dierkes, Jutta, 2021, "Replication data for: Cystatin C proteoforms in chronic kidney disease", https://doi.org/10.18710/NUNHDF, DataverseNO, V1

Study Description

Citation

Title:

Replication data for: Cystatin C proteoforms in chronic kidney disease

Identification Number:

doi:10.18710/NUNHDF

Authoring Entity:

Dierkes, Jutta (University of Bergen)

Other identifications and acknowledgements:

Dahl, Helene

Other identifications and acknowledgements:

Sandnes, Kristina

Other identifications and acknowledgements:

Welland, Natasha L.

Other identifications and acknowledgements:

Andresen, Iselin

Other identifications and acknowledgements:

Meyer, Klaus

Other identifications and acknowledgements:

Lysne, Vegard

Other identifications and acknowledgements:

Marti, Hans-Peter

Other identifications and acknowledgements:

Dierkes, Jutta

Producer:

University of Bergen

Software used in Production:

R studio

Distributor:

DataverseNO

Distributor:

University of Bergen

Access Authority:

Dierkes, Jutta

Depositor:

Dierkes, Jutta

Date of Deposit:

2021-04-24

Holdings Information:

https://doi.org/10.18710/NUNHDF

Study Scope

Keywords:

Medicine, Health and Life Sciences, Cystatin C, Kidney Diseases, Proteoform, chronic kidney disesase

Abstract:

Supplementary dataset to 'Cystatin C proteoforms in chronic kidney disease' This is a cross-sectional study on cystatin C proteoforms in patients with chronic kidney disease. The study was done at the University of Bergen and Haukeland University Hospital, Bergen, Norway. In total, 157 patients with various degrees of chronic kidney disease were included, and proteoforms of cystatin C were measured with MALDI-TOF. This dataset contains supplementary information.

<p> <p> ABSTRACT: <p> Cystatin C, a cysteine protease inhibitor, is used as a biomarker of renal function. It offers several advantages compared to creatinine, and formulas for the estimation of the glomerular filtration rate based on cystatin C have been developed. Recently, several proteoforms of cystatin C have been discovered, including an intact protein with a hydroxylated proline at the N-terminus, and N-terminal truncated forms. There is little knowledge about the biological significance of these proteoforms. <p> Methods: Cross-sectional study of patients with different stages of chronic renal disease (pre-dialysis n=53; hemodialysis n=51, renal transplant n=53). Measurement of cystatin C proteoforms by MALDI-TOF MS, assessment of medicine prescription using the first two levels of the Anatomical Therapeutic chemical system from patients’ records. <p>Results: Patients receiving hemodialysis had the highest cystatin C concentrations, followed by pre-dialysis patients and patients with a renal transplant. In all groups, the most common proteoforms were native cystatin C and CysC 3Pro-OH while the truncated forms made up 28%. The distribution of the different proteoforms was largely independent of renal function and total cystatin C. However, the use of corticosteroids (ATC-L02) and immunosuppressants (ATC-H04) considerably impacted the distribution of proteoforms. <p>Conclusion: The different proteoforms of cystatin C increased proportionally with total cystatin C in patients with chronic kidney disease. Prescription of corticosteroids and immunosuppressants had a significant effect on the distribution of proteoforms. The biological significance of these proteoforms remains to be determined.

Kind of Data:

clinical data

Methodology and Processing

Sources Statement

Data Access

Notes:

<a href="http://creativecommons.org/publicdomain/zero/1.0">CC0 1.0</a>

Other Study Description Materials

Related Materials

Gao, Jie; Meyer, Klaus; Borucki, Karin; Ueland, Per Magne. Multiplex Immuno-MALDI-TOF MS for Targeted Quantification of Protein Biomarkers and Their Proteoforms Related to Inflammation and Renal Dysfunction. Anal. Chem. 2018, 90, 5, 3366–3373. https://doi.org/10.1021/acs.analchem.7b04975

Dierkes, J., Dahl, H., Lervaag Welland, N. et al. High rates of central obesity and sarcopenia in CKD irrespective of renal replacement therapy – an observational cross-sectional study. BMC Nephrol 19, 259 (2018). https://doi.org/10.1186/s12882-018-1055-6

Other Study-Related Materials

Label:

00_README.txt

Text:

README file for dataset 'Cystatin C proteoforms in chronic kidney disease*

Notes:

text/plain

Other Study-Related Materials

Label:

Dahl_cysC_protforms_suppl_fig1.tif

Text:

supplementary figure 1. Proportion of proteoforms of CysC with estimated GFR (eGFR) based on creatinine, cystatin C or both, and with total cystatin C in patients with pre-dialysis chronic kidney disease (CKD 3-5), patients receiving hemodialysis (HD) and in renal transplant recipients (KTX).

Notes:

image/tiff

Other Study-Related Materials

Label:

PrescribedMedications.txt

Text:

Supplementary Table 2: Prescribed medications in the study population according to treatment group (CKD 3-5 chronic kidney disease stage 3-5, HD patients receiving hemodialysis, KTX renal transplant recipients) ATC anatomical therapeutic chemical classification

Notes:

text/plain

Other Study-Related Materials

Label:

StudyPopulation_characteristics_CKD.txt

Text:

Characteristics of study population by CKD stage

Notes:

text/plain